Symbionica | SYMBIONICA - Reconfigurable Machine for the new Additive and Subtractive Manufacturing of next generation fully personalized bionics and smart prosthetics

Summary

Medtech products belongs to a huge expanding market, in which Europe hosts some of the biggest global player, accounting for 30% of the world market and for more than 575,000 people employed by nearly 25,000 medical technology companies – 95% of which are SMEs.

Symbionica project focuses on the manufacturing of personalized bionics, smart endoprosthetics and exo-prosthetics that require geometric and functional customization.

The Symbionica concept integrates an innovative machine performing deposition of advanced materials and subtractive processes along with a supply chain distributed co-engineering platform for advanced design and full personalization involving all relevant stakeholders, design and engineering of the products and through-life services. Symbionica manufacturing solution is conceived as a multi-material AM machine for material deposition and ablation, flexible and reconfigurable in the working cube, the material processing, the technology and the manufacturing strategy, with an advanced closed loop control methodology for product and process quality monitoring.

This way Symbionica products are manufactured in one processing step, complex in shape, 3D structured and joint free. The Cooperative Design Platform will guarantee seamless data integration, reverse engineering from patient and parametric design to couple patient specific parts to standard ones.

At the end, a Bionic Through-life Sensing System will support the patient to approach and gradually become comfortable with the prosthesis by assisting him with an exercise plan, a physiology monitoring platform and an on-line prosthesis data collection.

The Symbionica consortium involves 3 LE, 6 SME and 2 RTD partners from 5 EU countries embracing the Medtech value chain from the patient and prosthetist to the technology providers of the mechatronics modules, IT solutions and control platforms.

Results, demos, etc. Show all and search (10)
Unfold all
/
Fold all
More information & hyperlinks
Web resources: http://www.symbionicaproject.eu
https://cordis.europa.eu/project/id/678144
Start date: 10-01-2015
End date: 30-09-2018
Total budget - Public funding: 7 305 000,00 Euro - 4 908 750,00 Euro
Cordis data

Original description

Medtech products belongs to a huge expanding market, in which Europe hosts some of the biggest global player, accounting for 30% of the world market and for more than 575,000 people employed by nearly 25,000 medical technology companies – 95% of which are SMEs.
Symbionica project focuses on the manufacturing of personalized bionics, smart endoprosthetics and exo-prosthetics that require geometric and functional customization. The Symbionica concept integrates an innovative machine performing deposition of advanced materials and subtractive processes along with a supply chain distributed co-engineering platform for advanced design and full personalization involving all relevant stakeholders, design and engineering of the products and through-life services.
Symbionica manufacturing solution is conceived as a multi-material AM machine for material deposition and ablation, flexible and reconfigurable in the working cube, the material processing, the technology and the manufacturing strategy, with an advanced closed loop control methodology for product and process quality monitoring. This way Symbionica products are manufactured in one processing step, complex in shape, 3D structured and joint free.
The Cooperative Design Platform will guarantee seamless data integration, reverse engineering from patient and parametric design to couple patient specific parts to standard ones.
At the end, a Bionic Through-life Sensing System will support the patient to approach and gradually become comfortable with the prosthesis by assisting him with an exercise plan, a physiology monitoring platform and an on-line prosthesis data collection.
The Symbionica consortium involves 3 LE, 6 SME and 2 RTD partners from 5 EU countries embracing the Medtech value chain from the patient and prosthetist to the technology providers of the mechatronics modules, IT solutions and control platforms.

Status

CLOSED

Call topic

FoF-10-2015

Update Date

27-10-2022
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Comment: MM-AM requires specific materials currently much more expensive in the case of Titanium powder, the higher cost is partially recovered by an efficient use of material (AM-Ti costs about 9 times more than conventional but AM has 95% efficiency compared to 20% of conventional machining
Comment: Symbionica will enable the integration of multiple AM technologies in one single machine to combine the most productive alternative with the most precise one with zero set-up time and zero material waste
Comment: 1) Use of raw material: Reduction inCO2 emissions >7.3 tCO2/year 2) Manufacturing process: energy reduction >220’000 tCO2/machine/year
Comment: 1) Use of raw material: Reduction inCO2 emissions >75 GJ/year 2) Manufacturing process: energy reduction >5’000 GJ/machine/year